Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

J. Schmidt, E. Braggio, K. M. Kortuem, J. B. Egan, Y. X. Zhu, C. S. Xin, R. E. Tiedemann, S. E. Palmer, V. M. Garbitt, D. McCauley, M. Kauffman, S. Shacham, M. Chesi, P. L. Bergsagel, A. K. Stewart

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

RNA interference screening identified XPO1 (exportin 1) among the 55 most vulnerable targets in multiple myeloma (MM). XPO1 encodes CRM1, a nuclear export protein. XPO1 expression increases with MM disease progression. Patients with MM have a higher expression of XPO1 compared with normal plasma cells (P<0.04) and to patients with monoclonal gammopathy of undetermined significance/smoldering MM (P<0.0001). The highest XPO1 level was found in human MM cell lines (HMCLs). A selective inhibitor of nuclear export compound KPT-276 specifically and irreversibly inhibits the nuclear export function of XPO1. The viability of 12 HMCLs treated with KTP-276 was significantly reduced. KPT-276 also actively induced apoptosis in primary MM patient samples. In gene expression analyses, two genes of probable relevance were dysregulated by KPT-276: cell division cycle 25 homolog A (CDC25A) and bromodomain-containing protein 4 (BRD4), both of which are associated with c-MYC pathway. Western blotting and reverse transcription-PCR confirm that c-MYC, CDC25A and BRD4 are all downregulated after treatment with KPT-276. KPT-276 reduced monoclonal spikes in the Vk*MYC transgenic MM mouse model, and inhibited tumor growth in a xenograft MM mouse model. A phase I clinical trial of an analog of KPT-276 is ongoing in hematological malignancies including MM.

Original languageEnglish (US)
Pages (from-to)2357-2365
Number of pages9
JournalLeukemia
Volume27
Issue number12
DOIs
StatePublished - Dec 2013

Keywords

  • CRM1
  • CRM1 Inhibitors
  • KPT-276
  • Myeloma
  • XPO1
  • exportin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276'. Together they form a unique fingerprint.

Cite this